74 related articles for article (PubMed ID: 8054714)
1. Introduction of oxygen into the alkyl chain of N-decyl-dNM decreases lipophilicity and results in increased retention of glucose residues on N-linked oligosaccharides.
Tan A; van den Broek L; Bolscher J; Vermaas DJ; Pastoors L; van Boeckel C; Ploegh H
Glycobiology; 1994 Apr; 4(2):141-9. PubMed ID: 8054714
[TBL] [Abstract][Full Text] [Related]
2. Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin. Structure-activity relationships.
Tan A; van den Broek L; van Boeckel S; Ploegh H; Bolscher J
J Biol Chem; 1991 Aug; 266(22):14504-10. PubMed ID: 1650361
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of alpha-glucosidase I inhibitors showing antiviral (HIV-1) and immunosuppressive activity.
van den Broek LA; Kat-Van Den Nieuwenhof MW; Butters TD; Van Boeckel CA
J Pharm Pharmacol; 1996 Feb; 48(2):172-8. PubMed ID: 8935166
[TBL] [Abstract][Full Text] [Related]
4. Cellular effects of deoxynojirimycin analogues: inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides.
Mellor HR; Neville DC; Harvey DJ; Platt FM; Dwek RA; Butters TD
Biochem J; 2004 Aug; 381(Pt 3):867-75. PubMed ID: 15128289
[TBL] [Abstract][Full Text] [Related]
5. Characterization of calf liver glucosidase I and its inhibition by basic sugar analogs.
Schweden J; Borgmann C; Legler G; Bause E
Arch Biochem Biophys; 1986 Jul; 248(1):335-40. PubMed ID: 2942110
[TBL] [Abstract][Full Text] [Related]
6. Effects of the glucosidase inhibitors nojirimycin and deoxynojirimycin on the biosynthesis of membrane and secretory glycoproteins.
Peyrieras N; Bause E; Legler G; Vasilov R; Claesson L; Peterson P; Ploegh H
EMBO J; 1983; 2(6):823-32. PubMed ID: 6227481
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a novel photoaffinity derivative of 1-deoxynojirimycin for active site-directed labeling of glucosidase I.
Romaniouk AV; Silva A; Feng J; Vijay IK
Glycobiology; 2004 Apr; 14(4):301-10. PubMed ID: 14718372
[TBL] [Abstract][Full Text] [Related]
8. Glucosylceramidase from calf spleen. Characterization of its active site with 4-n-alkylumbelliferyl beta-glucosides and N-alkyl derivatives of 1-deoxynojirimycin.
Legler G; Liedtke H
Biol Chem Hoppe Seyler; 1985 Dec; 366(12):1113-22. PubMed ID: 2936366
[TBL] [Abstract][Full Text] [Related]
9. Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
Langeveld M; van den Berg SA; Bijl N; Bijland S; van Roomen CP; Houben-Weerts JH; Ottenhoff R; Houten SM; van Dijk KW; Romijn JA; Groen AK; Aerts JM; Voshol PJ
Metabolism; 2012 Jan; 61(1):99-107. PubMed ID: 21816446
[TBL] [Abstract][Full Text] [Related]
10. Retention of glucose units added by the UDP-GLC:glycoprotein glucosyltransferase delays exit of glycoproteins from the endoplasmic reticulum.
Labriola C; Cazzulo JJ; Parodi AJ
J Cell Biol; 1995 Aug; 130(4):771-9. PubMed ID: 7642696
[TBL] [Abstract][Full Text] [Related]
11. Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile.
Godin G; Compain P; Martin OR; Ikeda K; Yu L; Asano N
Bioorg Med Chem Lett; 2004 Dec; 14(24):5991-5. PubMed ID: 15546715
[TBL] [Abstract][Full Text] [Related]
12. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase.
Overkleeft HS; Renkema GH; Neele J; Vianello P; Hung IO; Strijland A; van der Burg AM; Koomen GJ; Pandit UK; Aerts JM
J Biol Chem; 1998 Oct; 273(41):26522-7. PubMed ID: 9756888
[TBL] [Abstract][Full Text] [Related]
13. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing.
Platt FM; Neises GR; Karlsson GB; Dwek RA; Butters TD
J Biol Chem; 1994 Oct; 269(43):27108-14. PubMed ID: 7929454
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological characterisation of novel N-alkyl-deoxynojirimycin alpha-glucosidase inhibitors.
Rawlings AJ; Lomas H; Pilling AW; Lee MJ; Alonzi DS; Rountree JS; Jenkinson SF; Fleet GW; Dwek RA; Jones JH; Butters TD
Chembiochem; 2009 Apr; 10(6):1101-5. PubMed ID: 19294724
[TBL] [Abstract][Full Text] [Related]
15. Effect of a glucosidase inhibitor on the bioactivity and immunoreactivity of human immunodeficiency virus type 1 envelope glycoprotein.
Fenouillet E; Gluckman JC
J Gen Virol; 1991 Aug; 72 ( Pt 8)():1919-26. PubMed ID: 1678778
[TBL] [Abstract][Full Text] [Related]
16. An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
Liu M; Wang S; Zhou YD; Xiang T; Dong H; Yang K; Zhang XL
Bioorg Med Chem Lett; 2012 Jan; 22(1):564-70. PubMed ID: 22101135
[TBL] [Abstract][Full Text] [Related]
17. Processing and secretion of envelope glycoproteins of human immunodeficiency virus type 1 in the presence of trimming glucosidase inhibitor deoxynojirimycin.
Pal R; Kalyanaraman VS; Hoke GM; Sarngadharan MG
Intervirology; 1989; 30(1):27-35. PubMed ID: 2542177
[TBL] [Abstract][Full Text] [Related]
18. Transfer of free polymannose-type oligosaccharides from the cytosol to lysosomes in cultured human hepatocellular carcinoma HepG2 cells.
Saint-Pol A; Bauvy C; Codogno P; Moore SE
J Cell Biol; 1997 Jan; 136(1):45-59. PubMed ID: 9008702
[TBL] [Abstract][Full Text] [Related]
19. Comparison between 1-deoxynojirimycin and N-methyl-1-deoxynojirimycin as inhibitors of oligosaccharide processing in intestinal epithelial cells.
Romero PA; Saunier B; Herscovics A
Biochem J; 1985 Mar; 226(3):733-40. PubMed ID: 3157369
[TBL] [Abstract][Full Text] [Related]
20. Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells.
Zhang XL; Liu M; Xie P; Wan S; Tao Ye J; Zhou X; Wu J
Bioorg Med Chem Lett; 2004 Jul; 14(14):3789-92. PubMed ID: 15203163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
